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Mitochondrial tRNA mutationsWehave previously established a yeastmodel of mitochondrial (mt) diseases.We showed that defective respirato-
ry phenotypes due to point-mutations in mt tRNALeu(UUR), tRNAIle and tRNAVal could be relieved by overexpression
of both cognate andnon-cognate nuclearly encodedmt aminoacyl-tRNA synthetases (aaRS) LeuRS, IleRS andValRS.
More recently, we showed that the isolated carboxy-terminal domain (Cterm) of yeast mt LeuRS, and even short
peptides derived from the human Cterm, have the same suppressing abilities as the whole enzymes.
In this work, we extend these results by investigating the activity of a number of mt aaRS from either class I or II
towards a panel of mt tRNAs. The Cterm of both human and yeast mt LeuRS has the same spectrum of activity as
mt aaRS belonging to class I and subclass a, which is themost extensive among the whole enzymes. Yeast Cterm
is demonstrated to be endowed with mt targeting activity.
Importantly, peptide fragments β30_31 and β32_33, derived from the human Cterm, have even higher efﬁciency
as well as wider spectrum of activity, thus opening new avenues for therapeutic intervention. Bind-shifting
experiments show that the β30_31 peptide directly interacts with human mt tRNALeu(UUR) and tRNAIle, suggest-
ing that the rescuing activity of isolated peptide fragments is mediated by a chaperone-like mechanism.
Wide-range suppression appears to be idiosyncratic of LeuRS and its fragments, since it is not shared byCterminal
regions derived from humanmt IleRS or ValRS, which are expected to have very different structures and interac-
tions with tRNAs.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
AaRS are evolutionarily important enzymes on which the ﬁdelity of
genome decoding is based. All aaRS contain catalytic and anticodon
recognition domains to catalyse the aminoacylation reactions speciﬁc
for their cognate amino acids. Additionally, several aaRS have developed
editing activities to hydrolysemis-activated amino acids ormis-charged
tRNAs and prevent insertion of incorrect amino acids during protein
synthesis [1]. The canonical functions of aaRS, including aminoacylation
and editing activities, are highly conserved throughout the threeild type;MELAS,mitochondrial
sodes; aa, amino acid(s); aaRS,
the name of the amino acid, ab-
pe; rho°, mtDNA absent; MTS,
d Biotechnologies “C. Darwin”,
, Italy. Fax: +39 06 49912351.
nari).domains of life, i.e., archaea, bacteria and eukarya. Based on sequence,
structure and functional features, including catalytic domain topology
and tRNA esteriﬁcation site, aaRS have been assigned to two different
Classes, each divided into subclasses. Class I aaRS are characterized by
two structural motifs – HIGH and KMSKS – and have a Rossmann fold
dinucleotide-binding domain. This catalyses ATP dependent activation
of amino acids and transfer of activated aminoacyl–adenylates to the
2′-OH of the CCA sequence at the tRNA 3′-end. Enzymes with a Class I
catalytic domain include those active on amino acids Leu, Ile, Val, Met,
Cys, Arg, Glu, Gln, Tyr, and Trp. Class II aaRS employ three degenerate
motifs in an anti-parallel core of β strands to coordinate ATP binding,
and aminoacylate the 3′-OH of their cognate tRNAs. The classiﬁcation
of aaRS is conserved in evolution, with only a few exceptions [2].
However, during evolution from prokaryotes to vertebrates, including
mammals, certain aaRS have acquired other domains, unrelated to
aminoacylation and generally localized at the amino- or carboxy-
terminus [3]. The function of these additional domains include splicing
of structured RNAs, translation control, transcription regulation, signal
transduction, cell migration and others. In particular splicing of mt
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and in Neurospora crassa for mt TyrRS [5]. This activity has been
shown to be conserved in humanmt LeuRS although humanmt introns
are not present [6].
It has been shown that the overexpression of genes coding for mt
LeuRS, ValRS or IleRS, all belonging to Class I and subclass a, were able
to suppress the pathological phenotypes associated with mutated mt
tRNAs both in human and in yeast cells [7–13]. Further, we have
observed that human mt aaRS were able to suppress the defective
phenotypes of yeast mt tRNA mutants even more efﬁciently than the
orthologous yeast enzymes [7]. Moreover we have demonstrated that
the suppression activity does not require the catalytic activity of the
enzyme [14]. The three aforementioned aaRS bind very similar amino
acids, which only differ for the presence or position of a methyl group. It
has been reported that this similarity can result in mis-adenylation,
followed by mis-acylation by aaRS. Such mistakes are then corrected by
the editing domain that is present in mt LeuRS, IleRS and ValRS [15].
More recently, two novel aspects of the suppressing ability of aaRS
have been observed, namely the possibility to rescue the defective phe-
notypes ofmutants having substitutions inmt tRNALeu(UUR), tRNAIle and
tRNAVal by overexpressing i) non-cognate mt LeuRS, IleRS or ValRS
(cross-suppression activity); ii) a 67 aa Carboxy-terminal sequence de-
rived frommt LeuRS (Cterm suppression activity). The same properties
were demonstrated to be present in humanmt aaRS sequences in stud-
ies using cybrids, thus opening theway to new therapeutic perspectives.
To this end, it is important to note that the Cterm peptide, even though
lacking a canonical N-terminal mt targeting sequence (MTS), enters the
mitochondria of human cybrids and interactswithmt tRNAs in vitro [9].
Subsequently, we have shown that two isolated peptides derived from
the human mt LeuRS Cterm, named β30_31 (15 amino acids) and
β32_33 (16 amino acids), which are in contactwith the cognate tRNALeu
in known three-dimensional (3D) structures, are endowed with
suppressing activity comparable to the whole Cterm towards mt
tRNALeu(UUR), tRNAVal and tRNAIle mutants [7]. In view of potential ther-
apeutic applications, some relevant issues need to be addressed. In this
work, we aim at establishing: i) the extent of cross-suppression among
different mt aaRS; ii) whether the Cterminal regions of humanmt IleRS
and ValRS are endowed with suppressing and cross-suppressing abili-
ties analogous to the Cterm region of LeuRS; iii) whether the short
β30_31 and β32_33 peptides derived from human mt LeuRS Cterm
are able to rescue the defective phenotypes due to mutations in dif-
ferent mt tRNAs, as well as the previously studied mt tRNALeu(UUR),
tRNAIle and tRNAVal. Additionally, to investigate themolecular mech-
anism of the suppressing activity we tested the interaction between
human mt tRNAs (leu, ile and gly) and the β30_31 and β32_33Table 1
Suppression capability of Class I and Class II aaRS on mt tRNA mutants aminoacylated by Class
Glycerol growth of transforma
Class I aaRS
tRNA
Mutant
tRNA defect Glycerol growth
28 °C 37 °C
LeuRS ValRS
Sc
(NAM2)
Ia
Hs
(LARS2)
Ia
Sc
(VAS1)
Ia
VAL
C25T
[14]
Low amount of tRNAVal +/−+/− + [29]+ + [29]
+
+
[14,29]
+
LEU
A14G
[17]
Aminoacylation defect −− + [38]+ ++ ++
LEU
C25T
[17]
No tRNAs −− +
[14,29,38]
+
+ [29]
+
+ [29]
+
ILE T32C
[18]
No tRNAs −− + [18]+ ++ + [18]
+
GLN C6T
[40]
Structural and
aminoacylation defects
+/−− ++ +− +/−−
+ indicates growth similar to wild type;− indicates absence of growth; +/− indicates partiapeptides; demonstrated that the yeast mt LeuRS Cterm is endowed
with mt targeting activity; and analysed the available 3D structures
of aaRS–tRNA complexes to highlight the details of molecular
recognition.
2. Material and methods
2.1. Strains, media and growth conditions
S. cerevisiae strains are theWTMCC123MATa, ade2-1, ura3-52, leu2,
kar1-1 rho+ [16] and the isogenic mt tRNA mutants listed in Tables 1
and 2, which were originated by cytoduction crosses as previously de-
scribed [14]. Mutants are named with the three-letter code name of
the amino acid indicating the tRNA gene and the base substitution.
The original LeuA14G, LeuC25T, ValC25T and IleT32Cmutants were ob-
tained by biolistic transformation in order to obtain substitutions equiv-
alent to pathological mutations in the yeast model [14,17,18]. The
procedure is described in Rohou et al. [19] and details can be found in
Feuermann et al. 2003 [17], supplementary information. The original
mutants GlyG30T, PheC2T, PheC62T, AspC61T and the GlnC6T, and the
HisG51A mutants were obtained by MnCl2 random mutagenesis by M.
Bolotin Fukuhara and A. Tzagoloff, respectively, as previously described
[19–22].
The TUF1 null strain (MCC123ΔTUF1) was obtained as previously
described [23]. Strains were grown in YP complete medium (1% yeast
extract and 1% peptone from Difco) containing 3% glycerol, or 2% glu-
cose. Minimal mediumwas 0.7% yeast nitrogen base (Difco), 5% ammo-
nium sulphate and 2% glucose, supplemented with the necessary
auxotrophic requirements. For solid plates 1.5% agar (Difco) was
added to the abovemedia. The glycerol growth capability ofWT,mutant
and transformant cells was investigated by serial dilutions from concen-
trated suspensions (5 × 106 cell/ml) prepared from fresh single colony
spotted onto a unique plate.
2.2. Plasmids and cloning
Standard protocols [24] were used for Escherichia coli and yeast
transformations as well as plasmid preparations.
The vectors containing mt aaRS sequences are:
pNAM2 (kindly provided by Prof. C. Herbert) in which the yeast mt
LeuRS gene with its own promoter is cloned into the multi-copy
vector pFL44S [25];
pCtermNAM2 in which the sequence of the Carboxy-terminal
domain of NAM2 gene (from aa 829 to 894) is cloned in multi-copyI mt aaRS.
nt strains
Class II aaRS
IleRS
(ISM1) Ia
GluRS (MSE1) or Cyt
GlnRS (GLN4) Ib
TyrRS
(MSY1) Ic
GlyRS, HisRS, AspRS,
LysRS, PheRSHs
(VARS2)
Ia
+ [29]
+
++ +/−+/− ++ +/−+/−
++ ++ −− −− −−
+ [29]
+
++ −− −− −−
++ + [18]+ −− −− −−
+/−− +/−− +/−− +/−− +/−−
l growth.
Table 2
Suppression capability of Class I and Class II aaRS on mt tRNA mutants normally aminoacylated by class II mt aaRS.
Glycerol growth of transformant strains
Class I aaRS Class II aaRS
tRNA
Mutant
tRNA defect Glycerol
growth
28 °C
37 °C
LeuRS ValRS IleRS
(ISM1)
Ia
GluRS (MSE1) or Cyt
GlnRS (GLN4) Ib
TyrRS
(MSY1)
Ic
GlyRS
(GRS1)
IIa
HisRS
(HTS1)
IIa
AspRS
(MSD1)
IIb
LysRS
(MSK1)
IIb
PheRS
(MSF1)
IIc
Sc
(NAM2)
Ia
Hs
(LARS2)
Ia
Sc
(VAS1)
Ia
Hs
(VARS2)
Ia
ASP
C61T
[21]
3’ end
processing
−− − [38]
−
+− −− +/−− +− −− −− −− +− + [27]+ +− +−
GLY
G30T
[19]
No tRNAs −− −− −− −− −− −− −− −− −− −− −− −− −−
HIS
G51A
[40]
Structural
defect
+/−− +/−− +− +/−
+/−
+− +− +/−− ++ ++ + [38]
+
+/−− ++ ++
PHE
C2T
[20]
Ternary
complex
formation
+− +− +− +− +− +− +− +− +− +− +− +− +−
PHE
C62T
[20]
3′ end
processing
−− −− −− −− −− −− −− −− −− −− −− −− −−
+ indicates growth similar to wild type;− indicates absence of growth; +/− indicates partial growth.
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the inducible Gal1 promoter [7];
pVAS1 in which the yeast gene coding for the mt ValRS was cloned
into pCM262 by the “gap repair” technique [14];
pHTS1 (kindly provided by Prof. G. Fink), in which the yeast HTS1
gene with its own promoter, has been cloned in multi-copy vector
YEp24 [26];
pISM1 in which the entire ISM1 gene coding for yeast mt IleRS is
cloned into multi-copy vector pYES2.1/V5-His-TOPO (Invitrogen,
Life Technologies) under the inducible Gal1 promoter [18].
In the same vector we cloned the yeast mt TyrRS and GlyRS genes
(pMSY1 and pGRS1 respectively). The oligonucleotides for the PCR re-
actions were: TyrRS+: (5′-GGTAGACATTGTGAATCATG-3′) and TyRS-:
(5′-CATGTACTTTATATACCTCCC-3′); GRS1+ (5′-GTTAAGATTAAAAG
AATGAGTG-3′) and GRS1− (5′-CATTTATTTAGTCAGTTTCAGC-3′).
pMSD1 in which the ClaI–KpnI fragment containing the gene coding
for yeastmt AspRS and its promoter is subcloned from the YEp13 vector
[27] in the SmaI site of pELAC181plasmid;
pMSK1 in which the gene coding for yeast mt LysRS was cloned in
Yep13 was kindly provided by Prof A Tzagoloff;
pMSF1 in which the a subunit of yeast mt PheRS is cloned in YEp351
[20];
pGLN4 in which the gene coding for yeast cytosolic GlnRS is cloned
in the multi-copy vector pRS416 was kindly provided by Prof B. Krett
(we tested the suppression activity of this gene because the presence
of cytoplasmic GlnRS in the organelle and its involvement in mt Gln-
tRNA synthesis had been suggested by Rinehart et al. [28]. Moreover,
no evidence is available about transamidation of tRNAGlu to form
tRNAGln in S. cerevisiae mitochondria). We also tested the suppressing
effect of pMSE1 in which the gene coding for yeast mt GluRS is cloned
by PCR into multi-copy vector pYES2.1/V5-His-TOPO (Invitrogen, Life
Technologies) under the inducible Gal1 promoter. The oligonucleotides
for the PCR reactions were MSE 5′+ (5′-GAAAGGATCGTTCATAAAG-3′)
and MSE pst- (5′-GCTGCAGCGTATATGACGTATTTACATG-3′).
pLARS2 and pVARS2 in which the human gene coding for mt LeuRS
and ValRS, respectively, is cloned into pYES2 transcription vector under
the inducible Gal1 promoter [29];
pCtermLARS2, pβ30_31 and pβ32_33 are plasmids expressing frag-
ments of LARS2 gene (aa 837–903, 841–855, and 886–901, respectively),
cloned in the pYES2.1/V5-His-TOPO (Invitrogen, Life Technologies) vec-
tor under the inducible Gal1 promoter [7].In the same vector we cloned the human sequence coding for themt
IleRS variant from aa 880 to aa 945 (pCtermIARS2) by amplifying the in-
sert from pTUNEIARS2 [7] with CtermIARS2+ (5′-ATTTTCCTGAGCCA
GTAAAG-3′) and CtermIARS2− (5′-ATGAGTGCGTGTGCAATGCGAG-3′)
oligonucleotides.
pCtermVARS2 is the pYES2.1/V5-His-TOPO (Invitrogen, Life Tech-
nologies) vector expressing the mt ValRS variant from aa 908 to 974,
cloned by amplifying the insert with CtermVARS2+ (5′ATGGAGGTCG
TGCAGGTGC-3′) and VARS2− (5 ′TTAAGCCTGGGCCCAGCCG-3′) oligo-
nucleotides, from the pVARS2 vector.
pETUF1 is the multicopy pFL61 plasmid bearing the TUF1 gene with
its ownMTS and promoter [23]. The pEΔMTSTUF1 plasmid was obtain-
ed by amplifying the pETUF1 plasmid with ATG TUF10+ (5′-ATGGCA
GCTGCTTTTGATCG-3′) and TUF4- (5-CCAGTTGCATCAATAAGTC-3′)
primers and cloning the DNA fragment into the pYES2.1/V5-His-TOPO
(Invitrogen, Life Technologies) vector. For the pECterm-ΔMTSTUF1
plasmid we used a PCR fusion strategy whereby the Cterm domain
from pNAM2 (see above) was ampliﬁed using the following primers:
NamΔCtermEcoR1+ (5′-CGGAATTCCGATGAAATTCAAAAAGTTTCA
AAT-3′) and CtermNAMTUF11- (5′-GGAACGATCAAAAGCAGCTGCCTT
GTGGAATAAGAAACTAATCAC-3′). The other fusion fragment was ob-
tained from pETUF1 (see above) by amplifying the gene sequence
with opportune ligation primers: CtermTUF11+ GTGATTAGTTTCTTAT
TCCACAAGGCAGCTGCTTTTGATCGTTCC and TUF4- (see above). These
last two PCR products were ligated by PCR ampliﬁcation with
NAM2CtermEcoRI+ and TUF4− described above and cloned into the
pYES2.1/V5-His-TOPO (Invitrogen, Life Technologies).
For in vitro transcription the entire gene coding for WT human mt-
tRNALeu(UUR), tRNAIle and tRNAGly were inserted in the pGEM EASY vec-
tor (Promega). The insertswere generated by PCR from totalWThuman
ﬁbroblast DNA. The following oligonucleotide pairs containing the
T7 promoter and terminator: Hleu+T7 (5 ′-TAATACGACTCACTATAG
TTAAGATGGCAGAGCCCG-3′) and Hleu−T7 (5 ′-CAAAAAACCCCTCA
AGACCCGTTTAGAGGCCCCAAGGGGTTATGCTATGTTAAGAAGAGGAA
TTGAAC-3′);
Hile + T7 (5′-TAATACGACTCACTATAAGAAATATGTCTGATAA
AAG-3′) and Hile−T7 (5 ′-CAAAAAACCCCTCAAGACCCGTTTAGAGGC
CCCAAGGGGTTATGCTA TAGAAATAAGGGGGTTTAAGC-3′).
Hgly+T7 (5′-TAATACGACTCACTATAACTCTTTTAGTATAAATAG-3′)
and Hgly−T7 (5 ′-CAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAAG
GGGTTATGCTATACTCTTTTTTGAATGTTGT-3′);
Site directed mutagenesis was used to generate the pGEM EASY
vector (Promega) and insert mutations T4277C and C3256T in
A14G 
Leu
C6U
Gln
C2U
Phe
G30A
Gly
C62U
Phe
C61U
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Anticodon 
stem
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stem
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loop
U32C
Ile
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Fig. 1. Location of the mutations studied in this work in the context of a generic tRNA
cloverleaf structure. Mutant strains are named by letters indicating the mt tRNA gene
and base substitution. The mutated positions, indicated by arrows, are labelled according
to the standard numbering referring to yeast cytoplasmic tRNAPhe.
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pairs were: HileT4277C+ (5′-GAAATATGTCTGACAAAAGAGTTACT-
3′) and HileT4277C-(5′-AGTAACTCTTTTGTCAGACATATTTC-3′);
HleuC3256T + (5′-AGCCCGGTAATCGTATAAAACTTAAAAC-3′) and
HleuC3256T− (5′-GTTTTAAGTTTTATACGATTACCGGGCT-3′)
2.3. Band shift experiments
Puriﬁed amplicons were used as template in the transcription reac-
tion. We followed the HiScribe T7 in vitro transcription Kit (New
England BioLabs, Inc.) instruction designed for the production of small
RNAs (50–300 nucleotides ﬁnal length) with minor modiﬁcations:
[α-32P]UTP RNA labelling was performed as described by Sambrook
et al. [24]. After three hours of incubation at 42 °C the in vitro labelled
reaction was precipitated with Na acetate 0.3 M, glycogen 0.5 μg/μl.
The peptide NH2-MAVLINNKACGKIPV-COOH coding for the β30_31
(15 amino acids) region of human mt LeuRS Cterm domain was
commercially synthesized and HPLC puriﬁed by Primm Biotech ser-
vice. As control we used [Lys3]-Bombesin (15 amino acids in length,
Sigma-Aldrich).
The binding reaction was performed as previously described by Ke
et al. [30] using 4 mRad of the labelled reaction and different peptide
concentrations.
The complexes were separated on a 16 × 20 × 0.4 cm non-
denaturing Tris/Borate/EDTA (TBE) 15% polyacrylamide gel. Electro-
phoresis was performed at 200 V for 24 h at +4 °C.
A sample of commercial E. coli tRNAVal (Sigma-Aldrich) which has
the same length as mt tRNALeu(UUR) was loaded and visualized by
Ethidium bromide staining as a reference.
2.4. Structure and sequence analysis
The 3D structures of tRNA molecules determined in complex with
aaRS homologous to yeast or human enzymes listed in Tables 1 and 2
were downloaded from the Protein Data Bank (PDB, www.rcsb.org)
[31]. When more than one aaRS–tRNA complex from the same species
was available, only the structure with the best resolution was analysed
(see Supplementary Table S1). Structure visualization and analyses
were performed using the software InsightII (Accelrys Inc.) and
PyMOL (Schrödinger LLC).
Identiﬁcation of aaRS domains was performed by visual assessment
and reﬁnement of the initial InterPro [32] deﬁnition. Assignment of
secondary structure elements to Cterm domains was performed by
DSSP [33].
The sequence alignment between yeast and human mt tRNAs
aminoacylated by aaRS listed in Tables 1 and 2, or by their homologues
of known 3D structure, were downloaded from the mitotRNAdb and
tRNAdb databases (http://trnadb.bioinf.uni-leipzig.de/) [34]. Nucleo-
tides in contact with the cognate aaRS in 3D structures were calculated
using in house-built software (PDM et al., unpublished data). Two
atoms were considered to be in contact if their distance was lower
than or equal to 4.0 Å. The deﬁnition of identity nucleotides is from
Giegé et al. [35].
The multiple sequence alignment between human mt IleRS, ValRS
and LeuRS has been using the program Multialin obtained (http://
multalin.toulouse.inra.fr/multalin/multalin.html) [36].
3. Results
3.1. Mt aaRS exhibit cross suppressing activities towards several mt tRNA
mutants
We exploited our collection of yeast mutants, bearing different
substitutions located in various mt tRNA genes, to investigate the sup-
pressing and cross-suppressing ability of: i) the mt aaRS other than mt
LeuRS, IleRS and ValRS; ii) Sequences from the Cterminal regions ofmt IleRS andValRS; and iii)β30_31 andβ32_33 isolated regions derived
fromhumanmt LeuRSCterm [7]. Fig. 1 shows the localization of themu-
tations studied in this work in the context of a generic tRNA cloverleaf
structure [37]. The mutant strains were named by letters indicating
the mt tRNA gene and the base substitution. Mutations were obtained
either by random mutagenesis or biolistic transformation procedure.
They reside in different regions of the mt tRNA molecule and in mt
tRNAs aminoacylated by aaRS belonging to different Classes. To avoid
effects due to different nuclear backgrounds [14,38,39], we compared
growth phenotype and suppression activities using isogenic cells
obtained by cytoduction crosses withMCC123 rho° cells. The character-
ization of the mutants has been previously reported (for references see
Tables 1 and 2). The growth of mutants at 28 and 37 °C on a strictly re-
spiratory medium (YP containing 3% of glycerol) was compared to that
of the WT (Tables 1 and 2, column 3). We have previously shown that
the defects in mt protein synthesis of the mutants can be ascribed to
faulty tRNA aminoacylation [40], defective tRNA processing [20,21] or
subsequent steps at the ribosomal level and that, very often, defects
are accompanied by 3D structure alterations, which are indicated by al-
tered electrophoretic migration of the mutated tRNA (Tables 1 and 2,
column 2).
The results of representative suppression experiments are shown in
Fig. 2. The defective glycerol growth of LeuC25Tmutant with respect to
theWTwas suppressed by overexpression of both the cognatemt LeuRS
and the β30_31 peptide derived from it, but not by Class II enzymes mt
HisRS or PheRS (Fig. 2, panel A). The respiratory defect of the HisG51A
mutant was suppressed by both cognate mt HisRS and non-cognate
mt PheRS, both of which belong to Class II (intra-Class II suppression),
but not by Class I mt LeuRS (Fig. 2, panel B). Conversely, the defects as-
sociated with mutant PheC2T were not suppressed by the cognate mt
PheRS or non-cognate aaRS belonging to either the same (mt HisRS)
or different (mt LeuRS) Class. However, it is important to note that the
β30_31 sequence derived from mt LeuRS Cterm was able to suppress
the defects of both HisG51A and PheC2Tmutants with higher efﬁciency
than any of the whole enzymes tested.
A B C
WT
HisG51A
+empty plasmid
+pLeuRS
+pHisRS
+p 30_31
+pPheRS
28°C
WT
LeuC25T
+empty plasmid
+pLeuRS
+pHisRS
+p 30_31
+pPheRS
28°C 37°C
WT
PheC2T
+empty plasmid
+pLeuRS
+pHisRS
+p 30_31
+pPheRS
Fig. 2. Suppression activity of plasmids overexpressing mt aaRS sequences. Glycerol growth of serial dilutions of WT (MCC123) and isogenic mt tRNA mutants LeuC25T (A), HisG51A
(B) and PheC2T (C) transformedwith either emptymulti-copy plasmid or plasmid containing the yeast gene coding for humanmt leucyl-tRNA synthetase (pLeuRS), the Cterm β30_31se-
quence (pβ30_31) coding for a short peptide derived from the Ctermimal domain of humanmt leucyl-tRNA synthetase, the pHisRS and pPheRS, containing the yeast genes coding for mt
histidyl- and phenilalanyl-tRNA synthetases, respectively. Pictures have been taken after 5 days of growth at the indicated temperature.
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Class I mt aaRS with multi-copy plasmids overexpressing different mt
aaRS genes are reported in Table 1. The defects associated with muta-
tions in mt tRNALeu(UUR), tRNAIle and tRNAVal are efﬁciently cross-
suppressed by both yeast and human, cognate and non-cognate mt
aaRS belonging to the same Class and subclass (Ia), but not by the tested
mt aaRS from Class II or from different Class I subclasses Ib and Ic. The
only exception is the suppression by mt TyrRS (Class Ic), of the pheno-
type of the ValC25T mutant, which is aminoacylated by Class I, subclass
a, mt ValRS (Class Ia).
A different scenario is present in mutant GlnC6T. The defective phe-
notype of this mutant is only suppressed by mt LeuRS, at both temper-
atures in the case of the yeast gene (NAM2) and only at the permissive
temperature in the case of the human gene (LARS2) and not by any
other tested overexpressed gene. Therefore, the cross-suppression
ability of Class Ia mt aaRS is not shared by the other Class I mt aaRS
here analysed.
Table 2 reports the suppression, by Class I and II mt aaRS, of the
defects associated with mutations in mt tRNAs aminoacylated by Class
II mt aaRS. In this case, contrary to what has been reported in Table 1,
the defective phenotype of only two mutants (AspC61T and HisG51A)
is suppressed by the cognate aaRS and is cross-suppressed by other
Class II and Class I aaRS.
In summary, comparison of the data reported in Tables 1 and 2 high-
lights that the rescuing effect is most extended formt aaRS belonging to
Class I, and in particular subclass a. A special case is the HisG51Amutant
whose defect is suppressed by some Class II mt aaRS.
3.2. The cross-suppression activity of LeuRS carboxy-terminal domain and
sequences thereof is not shared by the aligned sequences of mt ValRS and
IleRS
We have previously demonstrated that the Cterm of human mt
LeuRS (67aa) is able to suppress defective phenotypes of both yeast
and human cells bearing mutations in mt tRNAs aminoacylated by
Class Ia mt aaRS [7,9,10]. Here we extend the investigation of the sup-
pressing ability of the Cterm by assessing its effect on the phenotype
of mutant tRNAs aminoacylated by mt aaRS from Class Ib and Class II.
Additionally, we examine the suppressing ability of the Cterminal re-
gions of mt ValRS and IleRS towards the same mutants examined for
mt LeuRS Cterm.
The Cterm of both human and yeast mt LeuRS and the β30_31 and
β32_33 sequences effectively suppress the defective phenotype of
most mutants (Table 3). In particular, all of them equally and effec-
tively suppress the phenotype due to mutations in all mt tRNAs
aminoacylated by Class Ia aaRS. The only exception is mutant IleT32C
whose phenotype is not suppressed by the Cterm from human LeuRSbut is suppressed by the short peptides derived from it. All yeast and
human mt LeuRS-derived fragments also suppress, albeit only at the
permissive temperature, the phenotype due to mutation in mt tRNAAsp,
aminoacylated by Class IIbmt AspRS. Interestingly, the short (15 and 16
amino acid long, respectively) β30_31 and β32_33 sequences suppress
the phenotype of several mutants, aminoacylated by Class IIa, much
more effectively than the whole Cterm domain of both yeast and
human mt LeuRS, from which they are derived. Strikingly, the ability
of HisG51A and PheC2T mutants overexpressing β30_31 and β32_33
sequences to grow on respiratory substrate is even higher than that of
the WT.
To evaluatewhether the suppressing activity of humanmtValRS and
IleRS resided in the Cterminal regions, as demonstrated for mt LeuRS,
the IARS2 and VARS2 sequences corresponding to residues 642–706
(65 amino acids) of mt IleRS and 768–834 (67 amino acids) of ValRS
were investigated (see Section 2). Fig. 3 shows the multiple alignment
of the Cterminal regions of human mt IleRS, ValRS and LeuRS. The mt
LeuRS Cterm domain region endowed with cross-suppression activity
(see Table 3), is underlined. The mt IleRS and ValRS sequences aligned
to this region have been used for suppression experiments. As shown
in Table 3, only the ValC25T mutant is suppressed by the Cterminal
sequences of both human mt IleRS and ValRS. These results indicate
that the wide cross-rescuing activity of human mt LeuRS Cterm is not
shared by the selected Cterminal sequences of mt IleRS and ValRS, and
that the determinants of the suppressing and cross-suppressing activity
possessed by thewhole enzymes (see Tables 1 and 2) possibly reside, at
least partially, in different regions of the molecules.
The phenotypes of mutants GlyG30A and PheC62T are not sup-
pressed by any of the investigated Cterminal sequences, as they were
not suppressed by any of the entire aaRS tested (Tables 1 and 2).
3.3. The β30_31 peptide derived from mt LeuRS Cterm interacts with
human mt tRNAs
To investigate whether the 15 amino acid long β30_31 peptide is
able to interact with human mt tRNAs we performed in vitro band
shift experiments.WTmt tRNALeu(UUR), tRNAIle and tRNAGlywere cloned
in the pGEM EASY vector and mutations m.3256CNT, equivalent to
LeuC25T, and m.4277 TNC in tRNAIle previously studied by Perli et al.
[8], were introduced by site directed mutagenesis. In all cases, the
in vitro transcription product was a unique band. Fig. 4 shows the elec-
trophoretic migration of WT mt tRNALeu(UUR) (panel A) and mt tRNAIle
reaction synthesis products (panel B). [α-32P]UTP tRNA labelling
was performed and 4mR of the reaction was used for the band shift
experiments.
Fig. 4 (panels C andD) shows the electrophoreticmobility of labelled
human mt tRNAs in the presence or absence of peptides. The results
Table 3
Suppression capability of Carboxy-terminal domain of mt LeuRS, and corresponding “Cterm” region of mt ValRS and mt IleRS.
tRNA
mutants
Glycerol
growth
28 °C 37 °C
Glycerol growth of transformant strains
Cterm
(NAM2)
Cterm
(LARS2)
β30_31
(LARS2)
β32_33
(LARS2)
“Cterm”
(VARS2)
“Cterm”
(IARS2)
tRNA aminoacylated by Class I aaRS GLNC6T +/−− +− +− +− +− +/−− +/−−
VALC25T +/−+/− + [7]+ ++ + [7]+ + [7]+ ++ ++
LEUA14G −− ++ ++ ++ ++ −− −−
LEUC25T −− + [7]+ ++ ++ ++ −− −−
ILET32C −− + [7]+ −− ++ ++ −− −−
tRNA aminoacylated by Class II
aaRS
ASPC61T −− +− +− +− +− −− −−
GLYG30A −− −− −− −− −− −− −−
HISG51A +/−− ++ ++ ++++ ++++ ++/− +/−−
PHEC2T +− +− +− +++ +++ +− +−
PHEC62T −− −− −− −− −− −− −−
“Cterm” is the Carboxy-terminal domain of the human mt ValRS and IleRS aligned with the suppressing Cterm domain of human mt LeuRS.
+ indicates growth similar to wild type;− indicates absence of growth; +/− indicates partial growth.
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compared to the WT (likely due to a conformational variation of the
molecule) and that both WT and mutant mt tRNALeu(UUR) and tRNAIle
undergo a band shift in the presence of the β30_31 peptide. The speci-
ﬁcity of this interaction is demonstrated by the absence of a band shift
in the presence of the 15 amino acid long peptide [Lys3]-Bombesin
(Fig. 4, panel C).
The same experiment was performed using WT mt tRNAGly. In this
case, in agreement with the lack of suppression of the GlyG30A mutant
phenotype following overexpression of the β30_31 sequence, we did
not observe changes in tRNA electrophoretic mobility in the presence
of the β30_31 peptide (Fig. 4, panel D).
3.4. Structure analysis shows that Cterminal domain regions of several aaRS
have different lengths, topologies and tRNA binding properties
To investigate the mode of interaction of aaRS listed in Tables 1
and 2 with cognate tRNA molecules, we analysed the 3D structures
of aaRS–tRNA complexes available from the PDB (see Supplementary
Table S1). Analysis of the domain architecture in these aaRS showed
that: i) not all aaRS comprise a Cterminal region after the anticodon
binding (or, in the case of AspRS, catalytic) domain (Fig. 5, panel A);Fig. 3.Multiple sequence alignment of the Cterminal region of humanmt IleRS (IARS2 gene), V
the amino acids with similar features are highlighted in grey. The 67 Cterm sequence of mt Leu
from mt ValRS (aa 768–834) aligned with the suppressing Cterm domain of mt LeuRS are undand ii) Cterminal regions belonging to different aaRS have different
3D structures, as highlighted by their different lengths and/or topol-
ogies (Fig. 5, panel B). Additionally, although all Cterminal regions
present in known structures make contact with tRNA molecules,
the speciﬁc tRNA nucleotides and Cterminal amino acids involved
in the interaction vary for different aaRS. Fig. 6 shows the tRNA nu-
cleotides interacting with different domains of cognate aaRS mole-
cules. The aaRS catalytic and anticodon binding domains are
generally involved in contacts with the tRNA acceptor and anticodon
arms, respectively. Conversely, both the speciﬁc position and identi-
ty of nucleotides interacting with the Cterminal region show very lit-
tle conservation between aaRS belonging not only to different
subclasses, but also to the same subclass. Further, the Cterminal do-
main of LeuRS from species belonging to the bacterial and archaeal
domains of life, have quite different lengths and topologies and in-
teract with different regions of the cognate tRNA molecules. While
LeuRS–tRNALeu is the only complex for which 3D structures from dif-
ferent domains of life are available, the higher sequence similarity of
human mt and cytoplasmic isoforms with bacterial and archaeal
LeuRS (data not shown), indicates that these differences have been
conserved in LeuRS of higher eukaryotes localized in different
compartments.alRS (VARS2 gene) and LeuRS (LARS2 gene). Identical amino acids are highlighted in black;
RS and the sequence of 65 amino acids frommt IleRS (aa 642–706) and of 67 amino acids
erlined. Boxes indicate sequences β30_31 and β32_33 of human mt LeuRS.
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Fig. 4. Products of in vitro transcription reaction and Band shift experiments. (A) Humanmt tRNALeu(UUR) and E. coli commercial tRNAVal, as reference, were loaded on 1% TBE agarose gel
and visualized by EtBr staining. Lanes: 1. PCR 100 bp LADDER; 2. Mt tRNALeu(UUR) (1/40 of reaction mixture); 3. Mt tRNALeu(UUR) (1/20 of reaction mixture); 4. Commercial E. coli tRNAVal
(3 μg). (B) Humanmt tRNAIle was loaded on 1% TBE agarose gel and visualized by EthidiumBromide staining. Lanes: 1. EcoRI/HindIII digestedλDNA; 2. tRNAIle (1/40 of reactionmixture).
(C) Band shift experimentswith in vitro [α32P]UTP labelled humanWT andmutatedm.3256C N Tmt tRNALeu(UUR) loadedwithout (−) or after incubationwith 7mMβ30_31 peptide and
7 mM [Lys3]-Bombesin (+), as control. (D) Band shift experiments with WT, mutated m.4277 T N C mt tRNAIle and WT mt tRNAGly loaded without (−) or after incubation with 7 mM
β30_31 peptide (+).
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We previously observed that human mt LeuRS Cterm domain can
be imported into the mitochondria [9,10] and that both human and
yeast peptides have a positive/negative residue ratio similar to the
N-terminal MTS of the whole enzymes [41,42]. To further investigate
the mt import we constructed a chimeric protein in which theFig. 5. Structure analysis of Cterminal regions in aaRS structures listed in Supplementary Table S
follows: orange, N-terminal region;magenta, catalytic domain; yellow, editing domain; cyan, an
in the sequence of S. cerevisiaemt TyrRS, but not visible in the structure; brown, other domain t
Cterminal regions indicated in panel A. Secondary structure elements are indicated by rectan
Rectangle width is proportional to the length of secondary structure elements.endogenous MTS of the mt protein synthesis elongation factor EF-Tu
(TUF1 gene) has been deleted and substituted by the Cterm ofmt LeuRS.
With this plasmid we transformed the strain deleted of the TUF1
gene unable to grow on glycerol containing media (mt EF-Tu in fact is
essential formt protein synthesis). Fig. 7 shows that the rescue obtained
with the chimera construct (pECterm-ΔMTSTUF1) is equivalent to that
obtained with the plasmid containing the WT TUF1 gene (pETUF1)1. (A) AaRS domain architecture. Domains are indicated by rectangles and colour-coded as
ticodon binding domain; green, Cterminal region; yellow–green, Cterminal region present
ypes. Rectanglewidth is proportional to domain length. (B) Secondary structure content of
gles and colour-coded as follows: blue, β-strands; red, α-helices; salmon, 3–10 helices.
Fig. 6. Sequence alignment of tRNA molecules aminoacylated by aaRS studied in this work, and of homologous aaRS of known 3D structure (bold). Sub: aaRS subclass. Source: species
abbreviations are as in Supplementary Table 1. PDB ID: identiﬁer of the 3D structure available from the PDB. TRNA stem regions are indicated by coloured boxes: orange, acceptor
stem; green,D-stem; blue, anticodon stem; red, T-stem. Numbers indicate the starting and ending nt of each stem region. TRNAnts in contactwith different aaRS regions in experimentally
determined 3D structures are indicated with differently coloured background: N-terminal region, orange; catalytic domain, magenta; editing domain, yellow; other inserted domains,
violet; anticodon binding domain, cyan; and Cterminal region, green. Identity nts (see text) identiﬁed for tRNAs whose sequences are reported in the alignment are indicated by black
borders. The positions corresponding to identity nts identiﬁed for other tRNAs, whose sequences are not present in the alignment, are indicated by asterisks.
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also a MTS function.4. Discussion
Mutations inmt tRNA genes cause themajority of mt diseases. Since
no cure for these diseases is currently available, the exploitation of the
suppression effect exerted bymt aaRS or their fragments for therapeutic
applications could be of highest importance.For this reason we have investigated the extension and the charac-
teristics of the suppression effects exerted by several mt aaRS towards
the respiratory defects due to mutations in cognate and non-cognate
mt tRNAs.
The results reported in thiswork represent an advancement towards
the elucidation of the mechanism by which the effects of mutations in
mt tRNAs are rescued by overexpression of cognate or non-cognate
mt aaRS.
The results reported in Tables 1 and 2 show that, with some excep-
tions (e.g. TyrRS), cross-suppression takes place in Class Ia mt aaRS,
3073P. Di Micco et al. / Biochimica et Biophysica Acta 1843 (2014) 3065–3074while it is limited among Class II mt aaRS with important exceptions for
mt tRNAAsp and tRNAHis mutants.
In principle, the suppressing ability of mt aaRS might be connected
with an increase of aminoacylation activity. However, as previously
mentioned we demonstrated that, at least in the case of mt LeuRS, the
rescuing of respiratory defects takes place even if catalytic activity is
absent [14]. This led us to suggest that the rescuing effect is mediated
by a chaperone-like activity, by which the altered structure of mutated
tRNA is corrected by the contact with the aaRS. Indeed, the Cterm of
human mt LeuRS, which does not possess catalytic activity, has been
shown to be endowed of the same suppression activity of the whole
enzyme [7].
Here we demonstrate by a chimeric construct (Fig. 7) that the yeast
mt LeuRS Cterm contains the speciﬁc sequence for mt targeting.
Additionally, short sequences derived from the human mt LeuRS
Cterm domain (β30_31 and β32_33), when overexpressed, can sup-
press not only the respiratory defects of the mutants aminoacylated
by Class I mt aaRS, but also of some additional mutants aminoacylated
by Class II mt aaRS (AspC61T, HisG51A and PheC2T) which were
not rescued by the whole enzyme (Tables 2 and 3). In some cases
(i.e., HisG51A and PheC62T mutants), the suppression is even more
effective than that obtained with the entire mt aaRS). This might be
explained by a less speciﬁc tRNA binding ability of the β30_31 peptide
compared with the entire enzyme. We can suggest that the short
peptidemight interact with several regions of themutated tRNA restor-
ing a structure required to exert its function thereby facilitating its rapid
utilization in the mt protein synthesis process. In the case of HisG51A,
the growthhigher thanWTmay be related to the presence of high levels
of mt histidylated tRNA previously reported for this mutant [40].
Additionally, we did not obtain suppression activity overexpressing
the Cterminal sequences of human mt IleRS and ValRS, aligned with
the Cterm of mt LeuRS (Table 3 and Fig. 3).
We also demonstrate by band-shift experiments that the β30_31
peptide, derived from the Cterm domain of mt LeuRS, interacts directly
with both WT and mutant human mt tRNALeu(UUR) and mt tRNAIle (see
Fig. 4). These interactions might force the mutated tRNA to resume a
structure that can restore normal mt protein synthesis. Conversely, we
did not observe band shift for human mt tRNAGly in the presence ofWT
MCC123 TUF1
+pECterm- MTSTUF1
MCC123 TUF1
+pETUF1
MCC123 TUF1
+empty plasmid
MCC123 TUF1
+pE MTSTUF1
Fig. 7. The Ctermdomain of yeastmt LeuRS can substitute themt targeting sequence ofmt
EF-Tu. Glycerol growth capability of WT (MCC123), the same strain deleted of the TUF1
gene (MCC123ΔTUF1) and of transformants bearing either the empty plasmid or one of
the following plasmids: pETUF1, containing the TUF1WT gene; pECtermΔMTSTUF1 con-
taining a chimeric construct where yeast mt LeuRS Cterm has substituted the endogenous
mt targeting sequence of TUF1; pEΔMTSTUF1 containing a mutated version of TUF1with-
out the mt targeting sequence. Picture was taken after 5 days of growth at 28 °C.the β30_31 peptide, consistent with the lack of suppression of the
defective phenotype of GlyG30T mutant by the overexpressed β30_31
sequence. Taken together, our results suggest that direct binding
between mutated tRNA and suppressive molecule is required for
suppression. The chaperone-like suppressor activity is expected to be
effective in the case of functional defects mediated at least in part, by
structural defects. Conversely, in the case of substitutions that do not re-
sult in tRNA structural defects chaperone-like suppressor molecules
may be less effective. Once the mutated tRNAs have recovered their
functionality, all the cellular defects derived from loss of tRNA function
are expected to be rescued.
An important point to discuss concerns the existence of a relation-
ship between the cross-suppression activity of mt aaRS and their
splicing activity. Here we show that several mt aaRS that have not yet
been reported to be involved in splicing are endowed with suppression
capability. On the other side, mt LeuRS that has been ﬁrst discovered
and studied as a splicing factor for yeast mt introns (which have com-
plex stem and loop RNA structures), is shown here to have an excep-
tionally wide range of suppressing activities. The splicing capability
has been shown to be localized in short sequences of the Cterm and
editing domains of mt LeuRS [43,44]. Both these domains and the splic-
ing activity are conserved in the human orthologue [6] even if the
human mtDNA does not contain introns. This character might suggest
that aaRS sequences involved in splicing/suppression might rescue the
phenotype due to several mutations in mt tRNA and possibly be used
for the therapy of a range of diseases associated with mutations in mt
tRNAs.
Thepattern of aaRS–tRNA interactions observed in known structures
indicates that, with the exception of a few regions, like the anticodon or
the CCA tail, different aaRS recognize different regions of their cognate
tRNA molecules.
However, inspection of the interactions established by Class Ia aaRS,
which is the only one for which different aaRS structures are available,
highlights that the position and, in a few cases, identity of contacting
nucleotides is relatively conserved, in agreement with the extensive
cross-suppression activity shown by aaRS belonging to this subclass.
In particular, the Cterm domain of LeuRS interacts with highly con-
served G and C nucleotides in the D-loop and T-loop, respectively. Con-
versely, the lack of cross-suppressing ability by nucleotides
contacted by the Cterminal domains of mt IleRS and ValRS may be
explained, at least in part, by their low extent of conservation.
This extensive study adds new insights on the possibility to identify
a single peptide endowedwith suppressing activity and able to alleviate
respiratory defects, due to mutations in most mt tRNAs. This might be
the basis for the ﬁrst speciﬁc cure for mt diseases due to mutations in
mt tRNAs. For this purpose, sequences derived from the mt LeuRS
Cterm should be preferentially investigated.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.09.011.
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